Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men

Magdalena Bentmar Holgersson, Aleksander Giwercman, Anders Bjartell, Frederick C W Wu, Ilpo T. Huhtaniemi, Terence W. O'Neill, Neil Pendleton, Dirk Vanderschueren, Michael E J Lean, Thang S. Han, Joseph D. Finn, Krzysztof Kula, Gianni Forti, Felipe F. Casanueva, G. Bártfai, Margus Punab, Yvonne Lundberg Giwercman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer. Methods: Men without prostate cancer history (n = 1,744) were selected from the European Male Ageing Study cohort of 40 to 79-year-old men from eight different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR variants (CAG repeatlength and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cutoff concentrations for further investigation of prostate cancer. Results: Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95% confidence intervals, 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG repeats (median 20 vs. 23, P <0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion: TheA-allele of theSNPrs1204038 gives a 65% higher risk of havingPSA above 3 ng/mLthan the G-allele in men without prostate cancer, and thereby an increased risk of being referred for further examination on suspicion of prostate cancer. Impact: Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.

Original languageEnglish
Pages (from-to)2048-2056
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Androgen Receptors
Prostate-Specific Antigen
Prostatic Neoplasms
Alleles
Single Nucleotide Polymorphism
Camellia
Biomarkers
Logistic Models
Genotype
Serum
Androgens
Linear Models
Cohort Studies
Confidence Intervals

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Holgersson, M. B., Giwercman, A., Bjartell, A., Wu, F. C. W., Huhtaniemi, I. T., O'Neill, T. W., ... Giwercman, Y. L. (2014). Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men. Cancer Epidemiology Biomarkers and Prevention, 23(10), 2048-2056. https://doi.org/10.1158/1055-9965.EPI-14-0376

Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men. / Holgersson, Magdalena Bentmar; Giwercman, Aleksander; Bjartell, Anders; Wu, Frederick C W; Huhtaniemi, Ilpo T.; O'Neill, Terence W.; Pendleton, Neil; Vanderschueren, Dirk; Lean, Michael E J; Han, Thang S.; Finn, Joseph D.; Kula, Krzysztof; Forti, Gianni; Casanueva, Felipe F.; Bártfai, G.; Punab, Margus; Giwercman, Yvonne Lundberg.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 10, 01.10.2014, p. 2048-2056.

Research output: Contribution to journalArticle

Holgersson, MB, Giwercman, A, Bjartell, A, Wu, FCW, Huhtaniemi, IT, O'Neill, TW, Pendleton, N, Vanderschueren, D, Lean, MEJ, Han, TS, Finn, JD, Kula, K, Forti, G, Casanueva, FF, Bártfai, G, Punab, M & Giwercman, YL 2014, 'Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men', Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 10, pp. 2048-2056. https://doi.org/10.1158/1055-9965.EPI-14-0376
Holgersson, Magdalena Bentmar ; Giwercman, Aleksander ; Bjartell, Anders ; Wu, Frederick C W ; Huhtaniemi, Ilpo T. ; O'Neill, Terence W. ; Pendleton, Neil ; Vanderschueren, Dirk ; Lean, Michael E J ; Han, Thang S. ; Finn, Joseph D. ; Kula, Krzysztof ; Forti, Gianni ; Casanueva, Felipe F. ; Bártfai, G. ; Punab, Margus ; Giwercman, Yvonne Lundberg. / Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 10. pp. 2048-2056.
@article{175ed77bbc2d4be494a0958f8f8dac1d,
title = "Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men",
abstract = "Background: Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer. Methods: Men without prostate cancer history (n = 1,744) were selected from the European Male Ageing Study cohort of 40 to 79-year-old men from eight different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR variants (CAG repeatlength and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cutoff concentrations for further investigation of prostate cancer. Results: Carriers of the SNP rs1204038 A-allele (16{\%} of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95{\%} confidence intervals, 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG repeats (median 20 vs. 23, P <0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion: TheA-allele of theSNPrs1204038 gives a 65{\%} higher risk of havingPSA above 3 ng/mLthan the G-allele in men without prostate cancer, and thereby an increased risk of being referred for further examination on suspicion of prostate cancer. Impact: Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.",
author = "Holgersson, {Magdalena Bentmar} and Aleksander Giwercman and Anders Bjartell and Wu, {Frederick C W} and Huhtaniemi, {Ilpo T.} and O'Neill, {Terence W.} and Neil Pendleton and Dirk Vanderschueren and Lean, {Michael E J} and Han, {Thang S.} and Finn, {Joseph D.} and Krzysztof Kula and Gianni Forti and Casanueva, {Felipe F.} and G. B{\'a}rtfai and Margus Punab and Giwercman, {Yvonne Lundberg}",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0376",
language = "English",
volume = "23",
pages = "2048--2056",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men

AU - Holgersson, Magdalena Bentmar

AU - Giwercman, Aleksander

AU - Bjartell, Anders

AU - Wu, Frederick C W

AU - Huhtaniemi, Ilpo T.

AU - O'Neill, Terence W.

AU - Pendleton, Neil

AU - Vanderschueren, Dirk

AU - Lean, Michael E J

AU - Han, Thang S.

AU - Finn, Joseph D.

AU - Kula, Krzysztof

AU - Forti, Gianni

AU - Casanueva, Felipe F.

AU - Bártfai, G.

AU - Punab, Margus

AU - Giwercman, Yvonne Lundberg

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer. Methods: Men without prostate cancer history (n = 1,744) were selected from the European Male Ageing Study cohort of 40 to 79-year-old men from eight different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR variants (CAG repeatlength and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cutoff concentrations for further investigation of prostate cancer. Results: Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95% confidence intervals, 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG repeats (median 20 vs. 23, P <0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion: TheA-allele of theSNPrs1204038 gives a 65% higher risk of havingPSA above 3 ng/mLthan the G-allele in men without prostate cancer, and thereby an increased risk of being referred for further examination on suspicion of prostate cancer. Impact: Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.

AB - Background: Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer. Methods: Men without prostate cancer history (n = 1,744) were selected from the European Male Ageing Study cohort of 40 to 79-year-old men from eight different European centers. Using linear and logistic regression models, with age and center as covariates, we investigated whether AR variants (CAG repeatlength and/or SNP genotype) were associated with having serum PSA concentrations above 3 or 4 ng/mL, which often are set as cutoff concentrations for further investigation of prostate cancer. Results: Carriers of the SNP rs1204038 A-allele (16% of the men) were more likely to have PSA>3 and 4 ng/mL (OR; 95% confidence intervals, 1.65; 1.13-2.40 and 1.87; 1.18-2.96, respectively) than G-allele carriers. They also had shorter CAG repeats (median 20 vs. 23, P <0.0005), but CAG repeat length per se did not affect the PSA concentrations. Conclusion: TheA-allele of theSNPrs1204038 gives a 65% higher risk of havingPSA above 3 ng/mLthan the G-allele in men without prostate cancer, and thereby an increased risk of being referred for further examination on suspicion of prostate cancer. Impact: Serum PSA as a clinical marker could be improved by adjustment for AR-genotype.

UR - http://www.scopus.com/inward/record.url?scp=84907483721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907483721&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0376

DO - 10.1158/1055-9965.EPI-14-0376

M3 - Article

VL - 23

SP - 2048

EP - 2056

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -